Please note: The information displayed on this page might be outdated.
4SC AG: (Xetra: VSC-DE; Mkt Cap $USM75.90) an epigenetic focused company developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s lead compound, Resminostat, is focused on Cutaneous T Cell Lymphoma but has unpartnered assets for Hodkins Lymphona, Colorectal Cancer, and HCC. Additional products are 4SC-202, an epigenetic anti-cancer compound that has completed Phase I clinical trial for the treatment of hematological tumors; and 4SC-205, an anti-cancer compound, which has completed Phase I clinical trial for the treatment of solid tumors.
Phase l or ll
Anti-inflammatory, Autoimmune, Hematology, Oncology
100MM - 500MM
Company Participants at Oktoberfest 2019 Wall Street "On Tap"
- Anna Niedl, Unknown
Ownership data is sourced through FactSet.